Drakes Maureen L, Czerlanis Cheryl M, Stiff Patrick J
Department of Medicine, Cardinal Bernardin Cancer Center, Loyola University Chicago, Building 112, 2160 South First Avenue, Maywood, IL 60153, USA.
Cancers (Basel). 2020 Nov 9;12(11):3301. doi: 10.3390/cancers12113301.
This review provides an update on the current use of immune checkpoint inhibitors (ICI) in female gynecologic cancers, and it addresses the potential of these agents to provide therapy options for disease management and long-term remission in advanced disease patients, where surgery, chemotherapy, and/or radiation fail to meet this goal. The topic of immune checkpoint inhibitors (ICI) blocking cytotoxic T lymphocyte associated protein-4 (CTLA-4) and the programmed death-1 (PD-1) axis has come to the forefront of translational medicine over the last decade for several malignancies. The text will focus primarily on a discussion of ovarian cancer, which is the most frequent cause of death of gynecologic cancers; endometrial cancer, which is the most often diagnosed gynecologic cancer; and cervical cancer, which is the third most common female gynecologic malignancy, all of which unfavorably alter the lives of many women. We will address the critical factors that regulate the outcome of these cancer types to ICI therapy, the ongoing clinical trials in this area, as well as the adverse immune responses that impact the outcome of patients given ICI regimens.
本综述介绍了免疫检查点抑制剂（ICI）在女性妇科癌症中的当前应用情况，并探讨了这些药物为晚期疾病患者提供疾病管理和长期缓解治疗选择的潜力，在这些患者中，手术、化疗和/或放疗无法实现这一目标。在过去十年中，免疫检查点抑制剂（ICI）阻断细胞毒性T淋巴细胞相关蛋白4（CTLA-4）和程序性死亡1（PD-1）轴的话题已成为多种恶性肿瘤转化医学的前沿。本文将主要聚焦于讨论卵巢癌（妇科癌症最常见的死亡原因）、子宫内膜癌（最常被诊断出的妇科癌症）和宫颈癌（第三大常见的女性妇科恶性肿瘤），所有这些癌症都对许多女性的生活产生了不利影响。我们将探讨调节这些癌症类型对ICI治疗反应的关键因素、该领域正在进行的临床试验，以及影响接受ICI治疗方案患者预后的不良免疫反应。
